[go: up one dir, main page]

ATE451386T1 - Mutantenformen von cholera holotoxin als adjuvans - Google Patents

Mutantenformen von cholera holotoxin als adjuvans

Info

Publication number
ATE451386T1
ATE451386T1 AT02752145T AT02752145T ATE451386T1 AT E451386 T1 ATE451386 T1 AT E451386T1 AT 02752145 T AT02752145 T AT 02752145T AT 02752145 T AT02752145 T AT 02752145T AT E451386 T1 ATE451386 T1 AT E451386T1
Authority
AT
Austria
Prior art keywords
amino acid
cholera
adjuvants
mutant forms
cholera holotoxin
Prior art date
Application number
AT02752145T
Other languages
English (en)
Inventor
Bruce Green
Randall Holmes
Michael Jobling
Duzhang Zhu
Original Assignee
Wyeth Corp
Univ Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Univ Colorado filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE451386T1 publication Critical patent/ATE451386T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT02752145T 2001-06-07 2002-06-05 Mutantenformen von cholera holotoxin als adjuvans ATE451386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29653701P 2001-06-07 2001-06-07
PCT/US2002/020978 WO2002098368A2 (en) 2001-06-07 2002-06-05 Mutant forms of cholera holotoxin as an adjuvant

Publications (1)

Publication Number Publication Date
ATE451386T1 true ATE451386T1 (de) 2009-12-15

Family

ID=23142433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02752145T ATE451386T1 (de) 2001-06-07 2002-06-05 Mutantenformen von cholera holotoxin als adjuvans

Country Status (13)

Country Link
US (3) US7285281B2 (de)
EP (1) EP1404368B1 (de)
JP (2) JP2004535187A (de)
KR (1) KR100898648B1 (de)
CN (2) CN1297316C (de)
AT (1) ATE451386T1 (de)
AU (1) AU2002346249B2 (de)
BR (1) BR0210225A (de)
CA (1) CA2449663A1 (de)
DE (1) DE60234695D1 (de)
IL (2) IL159210A0 (de)
MX (1) MXPA03011133A (de)
WO (1) WO2002098368A2 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
ATE493495T1 (de) * 2000-09-08 2011-01-15 Univ Maryland Biotech Inst Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen
ATE451386T1 (de) * 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
JP2005508143A (ja) * 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
CN100450551C (zh) * 2002-11-29 2009-01-14 中国医学科学院基础医学研究所 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途
WO2004083251A2 (en) * 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
DK1701968T3 (da) 2003-12-17 2015-06-22 Wyeth Llc Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling
BRPI0417689A8 (pt) 2003-12-17 2017-04-25 Elan Pharm Inc Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
CA2562037A1 (en) 2004-05-21 2005-12-08 Wyeth Altered fibronectin-binding protein of staphylococcus aureus
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2340848A3 (de) 2004-10-21 2011-09-14 Wyeth LLC Immunogene Zusammensetzungen von Staphylococcus epidermidis Polypeptide und Polynucleotide Antigenen
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2495307B9 (de) 2006-07-13 2018-05-02 Wyeth LLC Herstellung des Blutgerinnungsfaktors IX mit verbessertem Glykosylierungsmuster
EP2395077A1 (de) 2006-11-03 2011-12-14 Wyeth LLC Glycolysehemmstoffe in Zellkulturen
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
SI2115126T1 (sl) 2007-03-02 2015-06-30 Wyeth Llc Uporaba bakra in glutamata v celični kulturi za proizvodnjo polipeptidov
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
CN102316894A (zh) 2008-06-20 2012-01-11 惠氏有限责任公司 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
EP3301116A1 (de) 2008-08-25 2018-04-04 Dana Farber Cancer Institute, Inc. Konserviertes influenzahämagglutininepitop und antikörper dagegen
JP5693460B2 (ja) 2008-11-12 2015-04-01 セラクローン サイエンシーズ， インコーポレイテッド ヒトＭ２ｅペプチド免疫原
KR20140119165A (ko) 2009-06-22 2014-10-08 와이어쓰 엘엘씨 황색포도상구균 혈청형 5 및 8 협막 다당류 접합체 면역원성 조성물 및 이의 제조 방법
SG176837A1 (en) 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
ES2994878T3 (en) 2010-08-23 2025-02-03 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
KR20130114210A (ko) 2010-12-22 2013-10-16 와이어쓰 엘엘씨 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물
US9115363B2 (en) * 2011-03-09 2015-08-25 Ondek Pty Ltd Gene expression and eradication system in Helicobacter pylori
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
AU2013292617A1 (en) 2012-07-19 2015-01-22 Zoetis Llc Bovine influenza C virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
SG11201500566XA (en) 2012-08-16 2015-04-29 Pfizer Glycoconjugation processes and compositions
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
PL2935299T3 (pl) 2012-12-20 2020-05-18 Pfizer Inc. Sposób glikokoniugacji
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
US20160008449A1 (en) 2013-03-15 2016-01-14 Zoetis Services Llc CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
CN112336854B (zh) 2014-01-21 2024-11-26 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
EP3443983B1 (de) 2014-02-14 2022-07-20 Pfizer Inc. Immunogene glykoproteinkonjugate
EP3116539B1 (de) 2014-03-11 2018-10-10 Regents of the University of Minnesota Impfstoffe gegen porzines epidemisches diarrhoevirus und verfahren zur verwendung davon
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
NZ736238A (en) 2015-05-04 2022-07-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BR112018002919B1 (pt) 2015-08-14 2024-02-27 Zoetis Services Llc Composição imunogênica eficaz compreendendo uma cepa de mycoplasma bovis e usos da mesma para prevenção de doenças causadas por mycoplasma bovis
EP3402878A1 (de) 2016-01-11 2018-11-21 Zoetis Services LLC Neuartige impfstoffzusammensetzungen mit kreuzschutz für das porzine epidemische diarrhoevirus
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
US11191822B2 (en) 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
WO2018183666A1 (en) 2017-03-31 2018-10-04 Boston Medical Center Corporation Methods and compositions using highly converved pneumococcal surface proteins
AU2018290298B2 (en) 2017-06-23 2024-03-28 Affinivax, Inc. Immunogenic compositions
US20210085775A1 (en) * 2017-12-15 2021-03-25 Valneva Sweden Ab Methods and composition for preventing and/or treating cancer
EP3574915A1 (de) 2018-05-29 2019-12-04 Neovacs Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität
CA3148824A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
IL297244A (en) 2020-04-16 2022-12-01 Parimmune Sas Schistosoma-derived 28-kilodalton gst proteins for the treatment of vasculitis
EP4136095A1 (de) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2-spike-rezeptorbindungsdomäne und zusammensetzungen und verfahren dafür
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
IL301402A (en) 2020-09-17 2023-05-01 Inst Nat Sante Rech Med IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
CN120076825A (zh) 2022-09-29 2025-05-30 辉瑞公司 包含rsv f蛋白三聚体的免疫原组合物
CN117187301B (zh) * 2023-09-06 2024-08-20 迪福润丝(合肥)生物科技有限公司 一种含黏膜佐剂相关基因的重组ndv载体及相应的疫苗株和疫苗

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4883761A (en) 1986-03-25 1989-11-28 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
US5925546A (en) 1987-11-02 1999-07-20 Chiron S.P.A. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE69033600T2 (de) 1989-03-09 2001-04-05 American Cyanamid Co., Madison Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
US5786189A (en) 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US6290962B1 (en) 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5972336A (en) 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
CA2118824A1 (en) 1993-03-15 1994-09-16 Steven M. Baker Expression of pertussis holotoxin in bordetella pertussis
DE4322211A1 (de) * 1993-07-03 1995-01-12 Basf Ag Wäßrige, mehrphasige, stabile Fertigformulierung für Pflanzenschutz-Wirkstoffe und Verfahren zu ihrer Herstellung
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
WO1997005267A2 (en) 1995-07-26 1997-02-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
US5965354A (en) 1995-07-28 1999-10-12 Chiron Corporation Herpes simplex virus diagnostics
US6395964B1 (en) 1995-10-24 2002-05-28 The Texas A&M University System Oral immunization with transgenic plants
GB9603314D0 (en) 1996-02-16 1996-04-17 Biocine Spa Immunogenic detoxified mutant toxins
US6685949B1 (en) 1998-01-13 2004-02-03 The United States Of America As Represented By The Department Of Health & Human Services Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
WO1998032461A1 (en) 1997-01-29 1998-07-30 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant for hiv
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
WO1998045324A1 (en) 1997-04-04 1998-10-15 The Uab Research Foundation Use of cholera toxin mutants as mucosal adjuvants
IS4518A (is) 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20060121051A1 (en) * 1998-02-19 2006-06-08 Kenten John H Heat shock fusion-based vaccine system
ATE378066T1 (de) 1998-09-30 2007-11-15 Wyeth Corp Mutiertes cholera holotoxin als hilfsmittel
CN1191357C (zh) * 1998-12-22 2005-03-02 博伊斯·汤普生植物研究所 口服的免疫原性细菌肠毒素在转基因植物中的表达
EP1034792A1 (de) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasale Verabreichung von Pneumokokken-Polysaccharid Impfstoffen
WO2001089456A2 (en) 2000-05-19 2001-11-29 The Administrators Of The Tulane Educational Fund Hybrid lt-a/ct-b holotoxin for use as an adjuvant
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
ATE451386T1 (de) * 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ATE458496T1 (de) * 2002-01-14 2010-03-15 Novartis Vaccines & Diagnostic Hiv-vakzine und anwendungsverfahren
US20060069052A1 (en) 2003-02-14 2006-03-30 David Hone DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
WO2004083251A2 (en) * 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein

Also Published As

Publication number Publication date
EP1404368A4 (de) 2006-05-17
KR100898648B1 (ko) 2009-05-22
KR20040073965A (ko) 2004-08-21
US20080213303A1 (en) 2008-09-04
CN1297316C (zh) 2007-01-31
MXPA03011133A (es) 2004-12-06
US7285281B2 (en) 2007-10-23
CN1538854A (zh) 2004-10-20
IL159210A (en) 2010-04-29
WO2002098368A2 (en) 2002-12-12
EP1404368B1 (de) 2009-12-09
AU2002346249B2 (en) 2007-03-15
US20070116715A1 (en) 2007-05-24
CN1977971A (zh) 2007-06-13
BR0210225A (pt) 2004-09-08
JP2004535187A (ja) 2004-11-25
IL159210A0 (en) 2004-06-01
US7361355B2 (en) 2008-04-22
CA2449663A1 (en) 2002-12-12
US20040181036A1 (en) 2004-09-16
EP1404368A2 (de) 2004-04-07
JP2010017190A (ja) 2010-01-28
DE60234695D1 (de) 2010-01-21
WO2002098368A3 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
ATE451386T1 (de) Mutantenformen von cholera holotoxin als adjuvans
MXPA03011135A (es) Formas mutantes de holotoxina de colera como adyuvante.
DE69937571D1 (de) Mutiertes cholera holotoxin als hilfsmittel
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
Feinen et al. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant
MY125202A (en) Vaccine
WO2004030608A3 (en) Nanoemulsion vaccines
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1261377T3 (da) Immunmodulatoriske formuleringer og fremgangsmåder til anvendelse af disse
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
KR970705403A (ko) 비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant)
SE0102327D0 (sv) A novel engineered superantigen for human therapy
BR0015961A (pt) Antìgeno de neisseria de 85kda
NO20015074D0 (no) Nye sammensetninger
EP1385541A4 (de) Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
MA29459B1 (fr) Vaccins
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
BRPI0309001A2 (pt) bactérias gram-negativas atenuadas
WO2001070265A3 (en) Lipopeptide adjuvants
EA200200602A1 (ru) Вакцина, содержащая штаммы lactobacillus, для лечения воспаления предстательной железы и доброкачественной гиперплазии предстательной железы
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
WO2006095176A3 (en) Vaccine formulation
DK1307223T3 (da) Parenterale vaccineformuleringer og anvendelser deraf
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
SE0101030D0 (sv) Immunogenic cell surface proteins of helicobacter pylori

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties